Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nu-Med Plus (NUMD) EBITDA (2016 - 2025)

Nu-Med Plus' EBITDA history spans 10 years, with the latest figure at -$109691.0 for Q4 2021.

  • On a quarterly basis, EBITDA rose 78.19% to -$109691.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$830080.0, a 58.52% increase, with the full-year FY2025 number at -$48955.0, up 22.7% from a year prior.
  • EBITDA hit -$109691.0 in Q4 2021 for Nu-Med Plus, up from -$115717.0 in the prior quarter.
  • Over the last five years, EBITDA for NUMD hit a ceiling of $3.9 million in Q4 2017 and a floor of -$905419.0 in Q2 2020.
  • Historically, EBITDA has averaged -$71091.4 across 5 years, with a median of -$183789.0 in 2018.
  • Biggest five-year swings in EBITDA: soared 314.28% in 2017 and later plummeted 286.46% in 2018.
  • Tracing NUMD's EBITDA over 5 years: stood at $3.9 million in 2017, then plummeted by 109.02% to -$351627.0 in 2018, then surged by 42.36% to -$202668.0 in 2019, then tumbled by 148.11% to -$502832.0 in 2020, then surged by 78.19% to -$109691.0 in 2021.
  • Business Quant data shows EBITDA for NUMD at -$109691.0 in Q4 2021, -$115717.0 in Q3 2021, and -$250573.0 in Q2 2021.